Tocilizumab for the treatment of patients with rheumatoid arthritis and interstitial lung diseases: a case series
Manfredi, A.; Sebastiani, M.; Cassone, G.; Colaci, M.; Sandri, G.; Ferri, C.
Clinical and Experimental Rheumatology 36(2): 342
2018
ISSN/ISBN: 0392-856X PMID: 29465372 Document Number: 696241
Document emailed within 1 workday
Related Documents
Brandão, F.M.; Coelho, P.; Pinto, P.; Combe, B. 2010: Tocilizumab - a new step in rheumatoid arthritis treatment Acta Reumatologica Portuguesa 35(3): 302-312Shen, H.; Xia, L.; Lu, J. 2013: Interleukin-4 in rheumatoid arthritis patients with interstitial lung disease: a pilot study Indian Journal of Medical Research 138(6): 919-921
Van Herwaarden, N.; Herfkens-Hol, S.; van der Maas, A.; van den Bemt, B.J.F.; van Vollenhoven, R.F.; Bijlsma, J.W.J.; den Broeder, A.A. 2014: Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity Clinical and Experimental Rheumatology 32(3): 390-394
Terenzi, R.; Santoboni, G.; Bartoloni, E.; Alunno, A.; Luccioli, F.; Gerli, R. 2015: Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study Clinical and Experimental Rheumatology 33(3): 445
Nasonov, E.L. 2010: New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor) Terapevticheskii Arkhiv 82(5): 64-71
Juhl, P.; Thudium, C.S.; Gudmann, N.S.; Karsdal, M.A.; Bay-Jensen, A.-C.; Siebuhr, A.S. 2018: IL-6 receptor inhibition modulates type IIi collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study Clinical and Experimental Rheumatology 36(4): 568-574
Khurana, R.; Wolf, R.; Berney, S.; Caldito, G.; Hayat, S.; Berney, S.M. 2008: Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans Journal of Rheumatology 35(9): 1704-1708
Kawana, M.; Hatsuta, M.; Hirohara, M.; Kushida, K. 2019: Mindset for Pharmacists as an Expert of Pharmacotherapy-Case of Home-Care Rheumatoid Arthritis Patients with Multiple Diseases Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(Suppl 1): 93-96
Paulin, F.; Doyle, T.J.; Fletcher, E.A.; Ascherman, D.P.; Rosas, I.O. 2015: Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 67(5): 280-286
Hrncír, Z. 1994: The importance of administration of a series of methylprednisolone minipulses in the treatment of active rheumatoid arthritis Casopis Lekaru Ceskych 133(14): 440-442
Gossec, L.; Steinberg, G.; Rouanet, S.; Combe, B. 2015: Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. the French multicentre prospective PEPS Study Clinical and Experimental Rheumatology 33(5): 664-670
Yasuda, S. 2018: Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice in the use of T cell co-stimulatory inhibitor for patients with rheumatoid arthritis Clinical Calcium 28(5): 668-676
Lane, T.; Gillmore, J.D.; Wechalekar, A.D.; Hawkins, P.N.; Lachmann, H.J. 2015: Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature Clinical and Experimental Rheumatology 33(6 Suppl. 94): S46-S53
Labrune, S.; Huchon, G. 1991: Treatment of fibrosing interstitial lung diseases La Revue du Praticien 41(14): 1275-1277
Kusume, K.; Kitaichi, M.; Nagai, S.; Oshima, S.; Izumi, T.; Hanaoka, S.; Chihara, K. 1990: An open lung biopsy case of follicular bronchiolitis in rheumatoid arthritis Nihon Kyobu Shikkan Gakkai Zasshi 28(6): 906-912
Singh, N.; Garg, S.C. 1988: Rheumatoid arthritis presenting as arthritis mutilans with rheumatoid lung Journal of the Indian Medical Association 86(1): 14-15
Guerin, J.C.; Chevalier, J.P.; Kofmann, J.; Biot, N.; Bruinet, J.L.; Kalb, J.C.; Perrin-Fayolle, M. 1980: Drug induced interstitial lung diseases after treatment with cotrimoxazole. 2 cases La Nouvelle Presse Medicale 9(33): 2347
Zielonka, T.M.; Demkow, U.; Kowalski, J.; Kuś, J.; Krychniak-Soszka, A.; Radzikowska, E.; Skopińska-Rózewska, E.; Rowińska-Zakrzewska, E. 1997: Evaluation of angiogenic activity in sera from patients with interstitial lung diseases Pneumonologia i Alergologia Polska 65(11-12): 754-760
Iwanaga, T.; Hirai, M.; Ikeda, T.; Kishikawa, R.; Yamato, H.; Inatsu, K.; Fukuda, M.; Nogami, Y.; Yokota, K.; Tsurutani, H. 1994: Exertional hypoxemia evaluated by pulse oximetry in patients with interstitial lung diseases Nihon Kyobu Shikkan Gakkai Zasshi 32 Suppl: 127-134
Golden, M.R.; Katz, R.S.; Balk, R.A.; Golden, H.E. 1995: The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis Journal of Rheumatology 22(6): 1043-1047